Masatoshi Oka1,2, Sachiko Sekiya2, Ryoichi Sakiyama3, Tatsuya Shimizu4, Kosaku Nitta1. 1. Department of Medicine, Kidney Center. 2. Institute of Advanced Biomedical Engineering and Science, and. 3. Department of Clinical Engineering, Tokyo Women's Medical University, Tokyo, Japan. 4. Institute of Advanced Biomedical Engineering and Science, and shimizu.tatsuya@twmu.ac.jp.
Abstract
BACKGROUND: Although hepatocyte growth factor (HGF) has antifibrotic effects and is involved in angiogenesis and vasodilation, systemic administration of HGF to prevent kidney fibrosis is not a feasible strategy for suppressing interstitial fibrosis in patients with CKD. METHODS: We investigated a novel therapy involving HGF transgenic cell sheets grown in culture from human mesothelial cells and administered to rats with unilateral ureteral obstruction (UUO). We compared progression of fibrosis in rats with UUO that received one of five interventions: HGF-transgenic mesothelial cell sheets transplanted to the kidney surface, HGF-transgenic mesothelial cell sheets transplanted to thigh, mesotherial cell sheets transplanted to kidney, no sheets, or HGF injections. RESULTS: HGF transgenic cell sheets transplanted to the kidney strongly suppressed the induction of myofibroblasts and collagen in the kidney for 28 days; other interventions did not. Additionally, the HGF-secreting cell sheets ameliorated loss of peritubular capillaries and maintained renal blood flow. CONCLUSIONS: These findings suggest that cell sheet therapy is a novel and promising strategy for inhibiting progressive fibrosis in CKD.
BACKGROUND: Although hepatocyte growth factor (HGF) has antifibrotic effects and is involved in angiogenesis and vasodilation, systemic administration of HGF to prevent kidney fibrosis is not a feasible strategy for suppressing interstitial fibrosis in patients with CKD. METHODS: We investigated a novel therapy involving HGF transgenic cell sheets grown in culture from human mesothelial cells and administered to rats with unilateral ureteral obstruction (UUO). We compared progression of fibrosis in rats with UUO that received one of five interventions: HGF-transgenic mesothelial cell sheets transplanted to the kidney surface, HGF-transgenic mesothelial cell sheets transplanted to thigh, mesotherial cell sheets transplanted to kidney, no sheets, or HGF injections. RESULTS:HGF transgenic cell sheets transplanted to the kidney strongly suppressed the induction of myofibroblasts and collagen in the kidney for 28 days; other interventions did not. Additionally, the HGF-secreting cell sheets ameliorated loss of peritubular capillaries and maintained renal blood flow. CONCLUSIONS: These findings suggest that cell sheet therapy is a novel and promising strategy for inhibiting progressive fibrosis in CKD.
Authors: Rodney H Breau; Edward Clark; Bryan Bruner; Patrick Cervini; Thomas Atwell; Greg Knoll; Bradley C Leibovich Journal: Can Urol Assoc J Date: 2013 May-Jun Impact factor: 1.862
Authors: R Appasamy; M Tanabe; N Murase; R Zarnegar; R Venkataramanan; D H Van Thiel; G K Michalopoulos Journal: Lab Invest Date: 1993-03 Impact factor: 5.662
Authors: Kevin S Eardley; Chandrashekhar Kubal; Daniel Zehnder; Marcus Quinkler; Julia Lepenies; Caroline O Savage; Alec J Howie; Kirrenjit Kaur; Mark S Cooper; Dwomoa Adu; Paul Cockwell Journal: Kidney Int Date: 2008-06-04 Impact factor: 10.612
Authors: Veronica Finisguerra; Giusy Di Conza; Mario Di Matteo; Jens Serneels; Sandra Costa; A A Roger Thompson; Els Wauters; Sarah Walmsley; Hans Prenen; Zvi Granot; Andrea Casazza; Massimiliano Mazzone Journal: Nature Date: 2015-05-18 Impact factor: 49.962